Earlier this year, GW Pharmaceuticals became the center of attention of the cannabis industry after Jazz Pharmaceuticals plc (Nasdaq: JAZZ) acquired the cannabis biotech company for more than $7 billion.
GW is considered to be a trailblazer in the cannabis sector and was the first to receive approval from the US Food and Drug Administration for a cannabis-based treatment. We believe the company has set the stage for other biotech cannabis companies to be acquired as they continue to advance therapies through FDA clinical trials.
Cannabics is Focused on Advancing its Pipeline of Therapies
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) is a company that is trying to follow GW’s footprint and is a global leader in the development of cancer related cannabinoid-based medicine.
One of the reasons we are excited about Cannabics is related to the number of initiatives in its drug development pipeline. The company has four cancer treatment drug development projects, one pre-cancer antitumor drug development project, one palliative drug development project for the treatment of Cancer related Anorexia Cachexia Syndrome (CACS), and two early-stage drug discovery projects that target neurodegenerative and mental health diseases.
Last week, Cannabics announced the expansion of its research program with new drug development projects that target prostate cancer, neurodegenerative, and mental health diseases. The announcement comes after the company released promising initial pre-clinical data from its in-house drug discovery facility.
Study results indicate the potential efficacy of a variety of specific analytes for the indications that were tested. The experiments that were conducted on cell lines and human biopsies had received approval from the Helsinki Committee. Going forward, Cannabics plans to develop these drug candidates and to continue testing with animal models, while entering a drug regulatory development route for each indication.
One of the reasons we are excited about this development is related to the timing of it. The expansion comes after Cannabics’ published promising animal model study results for its proprietary colorectal cancer treatment drug candidate RCC-33. The company recently announced plans to enter the melanoma and breast cancer markets with new drug development projects and we are favorable on these indications from a total addressable market (TAM) standpoint.
The management team said that Cannabics has established a drug development pipeline that is focused on indications that are a $78.1 billion market in aggregate. According to Fortune Business Insights, the breast cancer market is estimated to grow from $21.58 billion in 2019 to $55.27 billion in 2027.
We believe the market underappreciates the growth prospects that are associated with these indications that Cannabics is focused on and will monitor how the management team continues to execute.
If you want to learn more about the companies which are trying to develop cannabis-based therapies, please send an email to firstname.lastname@example.org with the subject “Biotech Cannabis Companies” to be added to our distribution list.
For the fastest access to data on biotech cannabis companies, sign up for our free newsletter!
Pursuant to an agreement between StoneBridge Partners LLC and Cannabics Pharmaceuticals Inc. (CNBX) we have been hired for a period of 30 days beginning June 7, 2021 and ending July 7, 2021 to publicly disseminate information about (CNBX) including on the Website and other media including Facebook and Twitter. We are being paid $5,000 per month (CBNX) for or were paid “0” shares of restricted common shares. We own zero shares of (CNBX), which we purchased in the open market. We plan to sell the “ZERO” shares of (CNBX) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of (CNBX) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.
This press release may include predictions, estimates or other information that might be considered forward-looking within the meaning of applicable securities laws, including statements related to the Company’s ability to support its continued growth and fund the business’ sales and financial goals for at least the remainder of fiscal 2021 with proceeds remaining from its recent offering. While these forward-looking statements represent the Company’s current judgments, they are subject to risks and uncertainties that could cause actual results to differ materially, including risks and uncertainties associated with market conditions. You are cautioned not to place undue reliance on these forward-looking statements, which reflect the opinions of the Company’s management only as of the date of this release. Please keep in mind that the Company is not obligating itself to revise or publicly release the results of any revision to these forward-looking statements in light of new information or future events. When used herein, words such as: “potential,” “expect”, “look forward,” “believe,” “dedicated,” “building,” or variations of such words and similar expressions are intended to identify forward-looking statements.